



Universiteit
Leiden
The Netherlands

Systemic therapy in malignant mesothelioma: treat it or leave it

Gooijer, C.J. de

Citation

Gooijer, C. J. de. (2022, June 16). *Systemic therapy in malignant mesothelioma: treat it or leave it*. Retrieved from <https://hdl.handle.net/1887/3309449>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3309449>

Note: To cite this publication please use the final published version (if applicable).

Dianne de Gooyer

Systemic Therapy in Malignant Mesothelioma

Treat it or leave it

Colofon

The work described in this thesis was performed at the Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands

Author: Dianne de Gooijer
Cover: Dianne de Gooijer
Layout: Dianne de Gooijer
Printing: ProefschriftMaken
ISBN: 9789464238136

All rights reserved. No part of this publication may be reproduced, stored or transmitted in any form or by any means without prior permission of the holder of the copyright.

Financial support for printing of this thesis was kindly provided by the Oncology Graduate School Amsterdam (OGA).

Systemic Therapy in Malignant Mesothelioma

Treat it or Leave it

Proefschrift

ter verkrijging van de graad van doctor
aan de Universiteit Leiden,
op gezag van de rector magnificus
prof. dr. ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op donderag 16 juni 2022
klokke 16:15 uur

door

Cornedine Jannette Burgmeijer-de Gooijer

geboren te Wageningen

1990

Promotor:

Prof. dr. P. Baas

Copromotores:

dr. J.A. Burgers

dr. V. van der Noort

Leden promotiecommissie:

Prof. dr. J.J.C. Neefjes

Prof. dr. E.F. Smit

Prof. dr. M.E. van Leerdam

Prof. dr. S. Popat

dr. M.M. Stuiver

NHLI

AMC-UvA

Table of Content

Chapter 1	General introduction and thesis outline	6
PART I Chemotherapy in Malignant Mesothelioma		
Chapter 2	Current chemotherapy strategies in malignant pleural mesothelioma	20
Chapter 3	Switch maintenance gemcitabine after first line chemotherapy in patients with malignant mesothelioma; An investigator-initiated randomised open label phase 2 trial (NVALT19)	34
Chapter 4	Malignant peritoneal mesothelioma: Experience from two expert centres	62
PART II Immunotherapy in Malignant Mesothelioma		
Chapter 5	Immunotherapy in Malignant Pleural Mesothelioma	80
Chapter 6	Treat it or Leave it: Immuno-Oncology in Mesothelioma Observed by the Eyes of Argus	94
Chapter 7	Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program	102
PART III Predictive & Prognostic Factors in Malignant Mesothelioma		
Chapter 8	Prognostic value of CYFRA 21.1 in malignant mesothelioma: A brief report of the randomized phase II trial NVALT19	120
Chapter 9	Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical respons	126
Chapter 10	Optimizing Survival Prediction in Malignant Mesothelioma; Development and External Validation of A Clinical Prediction Model (MesoPro)	148
PART IV Lessons Learned		
Chapter 11	General discussion and future perspectives	172
	Summary/Samenvatting	184
PART V Appendices		
	List of publication	192
	Curriculum Vitae	196
	Dankwoord	200